Boolell M

No ORCID on file · 3 papers in corpus · active 2024-2025

Study types

  • rct 1
  • review 1

Condition tags

  • dysmenorrhea 2
  • endometriosis 2
  • chronic_pelvic_pain 1
  • dyspareunia 1
2025
Pain Reduction in Linzagolix-Treated Patients With Uterine Fibroids: A Secondary Mediation Analysis of the PRIMROSE 1 and 2 Phase 3 Trials.
BJOG : an international journal of obstetrics and gynaecology ·doi:10.1111/1471-0528.18190

ObjectiveAmong women with uterine fibroids (UFs), we assess the extent to which the linzagolix effect on pain alleviation is explained by its effect on reducing heavy menstrual bleeding (HMB) and fibroid volume (FV).DesignPost hoc analysis …

review 2024
A review of the pharmacology, clinical outcomes, and real-world effectiveness, safety, and non-contraceptive effects of NOMAC/E2
European journal of obstetrics & gynecology and reproductive biology: X ·doi:10.1016/j.eurox.2024.100283

Selecting an appropriate oral contraceptive can be challenging for healthcare professionals due to the abundance of marketed contraceptive options with different clinical and real-world effectiveness and safety profiles. Nomegestrol acetate…

rct 2024
Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3)
Human Reproduction ·doi:10.1093/humrep/deae076

STUDY QUESTION: Does linzagolix administered orally once daily for up to 3 months at a dose of 75 mg alone or 200 mg in combination with add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethindrone acetate, also known as norethisterone ac…